Sydney pharma Medical Therapies [ASX: MTY] has completed the purchase of the IP surrounding midkine protein-related technology assets from Japanese company Cell Signals Inc after receiving shareholder approval.

Cell Signals today traded all midkine protein-related IP rights to Medical Therapies, in exchange for 20 million shares of Medical Therapies stock.

These include patents, trademarks, manufacturing information and technical know-how, on top of all Cell Signals' stocks of midkine protein and reagents.

The agreement was announced in April. Midkine is a neurite growth promoting factor, active in oncogenesis and inflammation.